睿知中国医院研究地图
候选清单

南京南京医科大学

江苏省肿瘤医院

Jiangsu Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 8 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

江苏省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma14 篇牵头论文牵头 1 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma25 篇牵头论文牵头 2 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma16 篇牵头论文
  4. 胃癌Stomach cancer26 篇牵头论文
  5. 骨肉瘤Osteosarcoma0 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  8. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 4420242025: 332025

南京有 4 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2025-12
    登记号
    NCT05912582

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:江苏省肿瘤医院南京

  2. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  3. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题影像与人工智能复发与转移放疗技术
论文中的科室放疗科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. The Role of Ubiquitination Regulation in Nasopharyngeal Carcinoma.2026Cancer investigation
  2. Lactic Acid Metabolism-Related Gene May Act as a Prognostic Predictor by FARS2 in Nasopharyngeal Carcinoma.2025American journal of rhinology & allergy
  3. CircINADL promotes nasopharyngeal carcinoma metastasis by inhibiting HuR ubiquitin degradation and disrupting the hippo signaling pathway.2025Cellular signalling
  4. miR-205-5p Promotes the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells by Regulating CALM1.2025Critical reviews in immunology
  5. Long-term follow-up of protective effects on salivary and swallowing structures and improvement of late xerostomia and dysphagia by level IIb optimisation in clinical target volume of nasopharyngeal carcinoma.2024BMC cancer免费全文
  6. A pretreatment multiparametric MRI-based radiomics-clinical machine learning model for predicting radiation-induced temporal lobe injury in patients with nasopharyngeal carcinoma.2024Head & neck
  7. Effects of ambient temperature, relative humidity and absolute humidity on risk of nasopharyngeal carcinoma in China.2024International journal of cancer
  8. Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1hi and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.2024Oral oncology
  9. Depletion of SOD2 enhances nasopharyngeal carcinoma cell radiosensitivity via ferroptosis induction modulated by DHODH inhibition.2023BMC cancer免费全文
  10. METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinoma.2023Clinical and translational medicine免费全文
  11. LINC01376 promotes nasopharyngeal carcinoma tumorigenesis by competitively binding to the SP1/miR-4757/IGF1 axis.2023IUBMB life
  12. CircFOXM1 acts as a ceRNA to upregulate SMAD2 and promote the progression of nasopharyngeal carcinoma.2022Molecular genetics & genomic medicine免费全文
  13. Long non-coding RNA LUADT1 promotes nasopharyngeal carcinoma cell proliferation and invasion by downregulating miR-1207-5p.2021Bioengineered免费全文
  14. LncRNA EPB41L4A-AS2 represses Nasopharyngeal Carcinoma Metastasis by binding to YBX1 in the Nucleus and Sponging MiR-107 in the Cytoplasm.2021International journal of biological sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma即将招募NCT05912582牵头方2025-12 启动
  2. Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma已完成NCT06244394牵头方2023-06 启动
  3. NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation已终止NCT01694576牵头方II期2012-09 启动
  4. Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)已完成NCT01712919牵头方I/II期2010-05 启动
  5. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  6. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  7. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810状态不明NCT03260179研究中心I期2017-08 启动
  8. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  9. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
PubMed 以外找到的论文(未计入)26
  1. 1377P TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial2025Annals of Oncology论文
  2. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  3. Cisplatin-polyphenol complex liposomes reduce chemotherapy toxicity2025Chinese Chemical Letters论文
  4. Compare the Predictive Performance of Deep Learning and Radiomics Models for Predicting Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  5. Correlation between family care and stigma in patients undergoing radiotherapy for nasopharyngeal carcinoma: a retrospective observational analysis2024Chirurgia论文
  6. Deep Transfer Learning and Dosiomics for Predicting Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  7. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  8. LncRNA C7orf13 facilitates cell proliferation and metastasis in nasopharyngeal carcinoma via targeting miR ‐449c/ miR ‐28‐5p‐ FMNL2 axis2024Precision Medical Sciences论文
  9. A summary of our serial study: mechanism of invasion and metastasis in nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  10. Application and effect evaluation of case management nursing practice mode in patients with precision radiotherapy for nasopharyngeal carcinoma2023Precision Medical Sciences论文
  11. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  12. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  13. A case report of hypocalcemia after chemotherapy with albumin‐bound paclitaxel2022Precision Medical Sciences论文
  14. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  15. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  16. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  17. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  18. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  19. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  20. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  21. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  22. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  23. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  24. Effect of ear exercises on hearing loss in patients with nasopharyngeal carcinoma after radiotherapy2022Precision Medical Sciences论文
  25. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  26. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.9%。

牵头论文
25
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 5520222023: 1120232024: 8820242025: 882025

南京有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2025-12
    登记号
    NCT07435454

    年龄 70 岁 至 未注明(登记的条件)

    牵头:江苏省肿瘤医院南京

  2. 邀请入组
    Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
    分期
    III期
    开始
    2024-08
    登记号
    NCT07016737

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省肿瘤医院南京

  3. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  4. 正在招募
    Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2025-12
    登记号
    NCT07530094

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心南京

  5. 正在招募
    Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
    分期
    不分期
    开始
    2020-01
    登记号
    NCT04519905

    年龄 76 岁 至 未注明(登记的条件)

    牵头:复旦大学附属华东医院;另有 1 家列出的医院为研究中心上海、南京

  6. 正在招募
    Chemoradiotherapy in Unresectable Esophageal Cancer
    分期
    I/II期
    开始
    2019-10
    登记号
    NCT04278287

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院肿瘤医院;另有 4 家列出的医院为研究中心北京、南京、安阳、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗新辅助与综合治疗放疗
论文中的科室放疗科肿瘤内科影像/核医学科
牵头的论文25
  1. Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders.2026Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  2. Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study.2025BMC cancer免费全文
  3. Application of Esophageal Sponge Cytology in Screening Esophageal Squamous Cell Carcinoma in a High-Risk Region of China.2025Cancer medicine免费全文
  4. Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  5. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge in advanced esophageal squamous cell carcinoma: A retrospective study.2025Human vaccines & immunotherapeutics免费全文
  6. USP49 undergoes liquid-liquid phase separation and stabilizes RPA70 to induce radioresistance through homologous recombination repair in esophageal squamous cell carcinoma.2025International journal of biological macromolecules
  7. Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma.2025Journal of translational medicine免费全文
  8. lncRNA FENDRR Predicts Adverse Prognosis and Regulates the Development of Esophageal Squamous Cell Carcinoma Through Negatively Modulating miR-495-3p.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  9. Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First-Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study.2025Thoracic cancer免费全文
  10. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study.2024Cancer medicine免费全文
  11. Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer.2024Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  12. Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer.2024International immunopharmacology
  13. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.2024International immunopharmacology
  14. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.2024Journal for immunotherapy of cancer免费全文
  15. Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.2024Radiation oncology (London, England)免费全文
  16. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.2024Technology in cancer research & treatment免费全文
  17. Complete responses after neoadjuvant toripalimab and chemoradiotherapy for oesophageal squamous cell carcinoma: in situ and ex vivo 3.0 T MRI assessment.2024The British journal of surgery
  18. circFNDC3B promotes esophageal squamous cell carcinoma progression by targeting MYO5A via miR-370-3p/miR-136-5p.2023BMC cancer免费全文
  19. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.2022ESMO openRCT免费全文
  20. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.2022Frontiers in immunology免费全文
  21. PELI1 promotes radiotherapy sensitivity by inhibiting noncanonical NF-κB in esophageal squamous cancer.2022Molecular oncology免费全文
  22. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.2022Radiation oncology (London, England)免费全文
  23. Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma.2022The journal of pathology. Clinical research免费全文
  24. CircIMMP2L promotes esophageal squamous cell carcinoma malignant progression via CtBP1 nuclear retention dependent epigenetic modification.2021Clinical and translational medicine免费全文
  25. Tumor-infiltrating plasma cells are the promising prognosis marker for esophageal squamous cell carcinoma.2021Esophagus : official journal of the Japan Esophageal Society
中文论文(未计入)1
  1. [Efficacy and safety of PD-1 inhibitors combined with chemotherapy for the treatment of local recurrence at the primary tumor site of ESCC following definitive chemoradiotherapy or radiotherapy].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
  1. Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma正在招募NCT07435454牵头方II期2025-12 启动
  2. Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus状态不明NCT05424432牵头方II期2022-04 启动
  3. Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC状态不明NCT05394415牵头方I/II期2022-05 启动
  4. Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy邀请入组NCT07016737牵头方(推断)III期2024-08 启动
  5. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  6. Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma正在招募NCT07530094研究中心II期2025-12 启动
  7. Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)正在招募NCT04519905研究中心不分期2020-01 启动
  8. Chemoradiotherapy in Unresectable Esophageal Cancer正在招募NCT04278287研究中心I/II期2019-10 启动
  9. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC状态不明NCT05221658研究中心II期2022-08 启动
  10. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  11. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  12. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  13. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  14. Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma状态不明NCT03790553研究中心III期2018-10 启动
  15. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  16. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  17. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  18. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
PubMed 以外找到的论文(未计入)31
  1. 2120P Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. 2167P Comparative immune-pathological responses to neoadjuvant chemoimmunotherapy and chemotherapy in esophageal squamous cell carcinoma and development of a prognostic model2025Annals of Oncology论文
  3. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  4. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  5. Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma2025Precision Medical Sciences论文
  6. Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.2025Journal of Clinical Oncology论文
  7. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N2025Journal of Clinical Oncology论文
  8. Tislelizumab plus short-course chemo-radiotherapy for conversion therapy of unresectable ESCC (LATE): A proof-of-concept, phase Ib trial.2025Journal of Clinical Oncology论文
  9. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncology撤稿
  10. 188P The impact of pathological regression of primary tumor and lymph node on recurrence and survival in patients with locally advanced esophageal squamous cell carcinoma following neoadjuvant chemo-immunotherapy2024Annals of Oncology论文
  11. Abstract LB003: Comprehensive multi-omics analysis unveils NFE2L2/KEAP1 mutations as key drivers of treatment resistance in esophageal squamous cell carcinoma during chemoradiotherapy2024Cancer Research会议摘要
  12. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  13. Effectiveness and safety of first-line serplulimab in patients with metastatic/locally advanced esophageal carcinoma (EC): A real-world study.2024Journal of Clinical Oncology会议摘要
  14. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  15. Impact of immunotherapy combined with neoadjuvant chemotherapy or chemoradiotherapy on perioperative safety in locally advanced esophageal squamous cell carcinoma (LA-ESCC): A retrospective propensity score-matched analysis.2024Journal of Clinical Oncology会议摘要
  16. Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.2024Journal of Clinical Oncology会议摘要
  17. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncology论文
  18. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Research会议摘要
  19. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  20. Association of PIWI-interacting RNA-23210 with tumor metastasis in esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  21. Identification of secretory factors associated with suppressive tumor microenvironment in esophageal cancer2023Research Square预印本
  22. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology会议摘要
  23. Two cycles versus four cycles of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, multicenter and randomized study.2023Journal of Clinical Oncology会议摘要
  24. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncology论文
  25. Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).2022Journal of Clinical Oncology会议摘要
  26. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  27. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  28. SCALE-1: Safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus.2022Journal of Clinical Oncology会议摘要
  29. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  30. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncology会议摘要
  31. Phase-II study of toripalimab combined with neoadjuvant chemotherapy for the treatment of resectable esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.1%。

牵头论文
16
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 5520232024: 2220242025: 332025

南京有 7 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室肿瘤内科普外/肝胆胰外科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文16
  1. Nicotinamide metabolism affects the prognosis of hepatocellular carcinoma by influencing the tumor microenvironment.2025Cytokine
  2. Targeting HCG18 counteracts ferroptosis resistance via blocking the miR-30a-5p/RRM2/GSS pathway in hepatocellular carcinoma.2025International journal of biological sciences免费全文
  3. Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study.2025Investigational new drugs免费全文
  4. Bile acid conjugated chitosan nanoparticles promote the proliferation and epithelial-mesenchymal transition of hepatocellular carcinoma by regulating the PI3K/Akt/mTOR pathway.2024Carbohydrate research
  5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.2024Journal of gastroenterology and hepatology
  6. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.2023Advances in therapy
  7. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.2023Cancer biomarkers : section A of Disease markers免费全文
  8. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.2023Cancer medicine免费全文
  9. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.2023Frontiers in immunology免费全文
  10. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC.2023Hepatology (Baltimore, Md.)免费全文
  11. Egr1/HSP70 Promoter-Driven Activation of Gene Expression for Synergistic Anti-Hepatoma Using PEI-MZF Nanoparticles and Radiation.2022International journal of nanomedicine免费全文
  12. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma.2022Journal for immunotherapy of cancer免费全文
  13. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3.2021Aging免费全文
  14. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  15. Combination of Tertiary Lymphoid Structure and Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients With Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  16. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.2021Theranostics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  3. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  4. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  5. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810状态不明NCT03260179研究中心I期2017-08 启动
  6. Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma已完成NCT01210495研究中心II期2010-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.3%。

牵头论文
26
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 7720222023: 3320232024: 3320242025: 992025

南京有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  3. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  4. 即将招募
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07902596

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 6 家列出的医院为研究中心上海、南京、石家庄、苏州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期免疫与靶向药物手术
论文中的科室普外/肝胆胰外科肿瘤内科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文26
  1. tRF-Ser-TGA-011 impedes gastric cancer progression by targeting the MAP3K13/JNK signaling cascade.2026Cellular signalling
  2. Silencing of RNFT2 suppresses cell proliferation and migration through mTORC1 signaling pathway in gastric cancer.2025Amino acids免费全文
  3. The levels of plasma MiR-9 and MiR-106a are associated with the development of peritoneal carcinomatosis in patients with gastric cancer.2025BMC cancer免费全文
  4. The efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for locally advanced gastric cancer: a single-center, real-world clinical study.2025Cancer immunology, immunotherapy : CII免费全文
  5. COL1A1-positive endothelial cells promote gastric cancer progression via the ANGPTL4-SDC4 axis driven by endothelial-to-mesenchymal transition.2025Cancer letters
  6. Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer.2025Cancer research
  7. Unveiling the Power of Mitochondrial Fission and Fusion: A Five- Gene Signature for Personalized Prognosis in Gastric Cancer.2025Current medicinal chemistry
  8. N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  9. Tunnel anastomosis: a modified flap technique in esophagogastrostomy as a novel antireflux technique after proximal gastrectomy.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  10. Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer.2025World journal of surgical oncology免费全文
  11. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy.2024Gastroenterology
  12. Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study.2024Human vaccines & immunotherapeutics免费全文
  13. Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer.2024Journal of gastrointestinal cancer免费全文
  14. Construction and evaluation of the functional polygenic risk score for gastric cancer in a prospective cohort of the European population.2023Chinese medical journal免费全文
  15. Quantitative parameters in novel spectral computed tomography for assessing gastric cancer and cell proliferation.2023European journal of radiology
  16. Biomimetic black phosphorus nanosheets codeliver CDK9 and BRD4 inhibitors for gastric cancer targeted therapy.2023Journal of materials chemistry. B
  17. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: A propensity score-matched analysis.2022Asian journal of surgery
  18. Deep muscularis propria tumor invasion without lymph node metastasis as a unique subclassification of stage IB gastric cancer: a retrospective study.2022BMC gastroenterology免费全文
  19. Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer.2022Cancer immunology research
  20. tRF-Val-CAC-016 modulates the transduction of CACNA1d-mediated MAPK signaling pathways to suppress the proliferation of gastric carcinoma.2022Cell communication and signaling : CCS免费全文
  21. A novel monoclonal antibody associated with glucoside kills gastric adenocarcinoma AGS cells based on glycosylation target.2022Journal of cellular and molecular medicine免费全文
  22. MiR-200a-3p promotes gastric cancer progression by targeting DLC-1.2022Journal of molecular histology
  23. Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer.2022Life sciences
  24. Down-regulation of estrogen-related receptor alpha (ERRα) inhibits gastric cancer cell migration and invasion in vitro and in vivo.2021Aging免费全文
  25. MiR-200c-3p aggravates gastric cell carcinoma via KLF6.2021Genes & genomics免费全文
  26. Clinicopathological features and risk factors analysis of lymph node metastasis and long-term prognosis in patients with synchronous multiple gastric cancer.2021World journal of surgical oncology免费全文
中文论文(未计入)1
  1. [Efficacy and feasibility of tunnel esophagogastrostomy to perform proximal gastrectomy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma状态不明NCT05237349牵头方(推断)II期2022-03 启动
  2. A Benefit Population Atlas of nICT Versus nCT for LAGC已完成NCT07098104牵头方(推断)2019-11 启动
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  5. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma即将招募NCT07902596研究中心2026-10 启动
  6. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  7. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  8. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  9. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  10. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  11. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  12. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)已完成NCT03399110研究中心III期2018-01 启动
  13. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810状态不明NCT03260179研究中心I期2017-08 启动
  14. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  15. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study状态不明NCT03121729研究中心不分期2017-06 启动
  16. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  17. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)已完成NCT02745509研究中心不分期2016-03 启动
  18. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  19. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  20. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  21. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  22. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 25 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Long noncoding RNA MEG3 play an important role in osteosarcoma development through sponging microRNAs.2019Journal of cellular biochemistry

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

南京有 11 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 15 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南京有 5 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

江苏省肿瘤医院

Jiangsu Cancer Hospital

南京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Affiliated Cancer Hospital of Nanjing Medical University; Nanjing Medical University Affiliated Cancer Hospital; Jiangsu Cancer Hospital Affiliated to Nanjing Medical University; Affiliated Cancer Hospital ( Jiangsu Cancer Hospital); Jiangsu Cancer Centre; Jiangsu Provincial Cancer Hospital; Affiliated Cancer Hospital (Jiangsu Cancer Hospital); Jiangsu Cancer Hosiptal

提出更正下载数据